EGFR and non-small cell lung carcinoma: Among 67 patients with EGFR mutated NSCLC after PD to EGFR TKIs, and increased EGFR mutation abundance on ctDNA was evident in 37% of cases, while in the majority of cases, the allelic fraction of EGFR activating mutation was either stable (19%) or reduced (43%).